Want to see IN:SYNCOMF full AI Analyst Report?
SYNCOMF Stock Chart & Stats
₹15.88
₹0.19(1.32%)
At close: 4:00 PM EDT
₹15.88
₹0.19(1.32%)
Day’s Range― - ―
52-Week Range₹10.21 - ₹18.69
Previous CloseN/A
Volume4.93M
Average Volume (3M)249.72K
Market Cap
₹13.67B
Enterprise Value₹13.72K
Total Cash (Recent Filing)₹1.13B
Total Debt (Recent Filing)₹14.74M
Price to Earnings (P/E)18.5
Beta1.56
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.86
Shares Outstanding940,000,000
10 Day Avg. Volume232,913
30 Day Avg. Volume249,719
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.34
Price to Sales (P/S)1.99
P/FCF Ratio21.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
De-levered Balance SheetA materially de-levered balance sheet with negligible debt and equity of ~₹4.15B materially reduces solvency risk and interest burden. This improves financial flexibility to fund capex, working capital or M&A over the next 2-6 months and supports resilience versus cyclical shocks.
Improved ProfitabilityA sustained net margin improvement indicates stronger pricing power, cost control or mix shift, translating into higher earnings per unit of revenue. Consistently elevated margins enhance cash generation potential and buffer returns even if revenue growth moderates.
Rebounded Cash GenerationA clear rebound to strong operating and free cash flow that covers most reported earnings signals improving conversion of profits into cash. That durable cash generation strengthens liquidity, funds organic investment and reduces reliance on external financing over the medium term.
Bears Say
Revenue Decline And Margin PressureA recent revenue decline combined with notable gross-margin compression suggests structural mix shifts, pricing pressure or rising input costs. Persisting top-line softness and weaker gross margins could limit sustainable earnings growth and test the durability of improved net margins.
Volatile Cash-Flow HistoryAlthough FY2026 shows strong cash flow, multi-year volatility in operating and free cash flow indicates inconsistent conversion from earnings to cash. This historical unpredictability raises execution risk and suggests cash-backed plans may be less reliable in stressed periods.
Incomplete ROE Data For Latest YearAbsence of FY2026 ROE limits visibility on current capital efficiency after major balance-sheet shifts. With equity having expanded and debt cut dramatically, lack of up-to-date ROE hinders assessment of whether shareholder returns kept pace with lower leverage.
Syncom Formulation (India) Ltd. News
SYNCOMF FAQ
What was Syncom Formulation (India) Ltd.’s price range in the past 12 months?
Syncom Formulation (India) Ltd. lowest stock price was ₹10.21 and its highest was ₹18.69 in the past 12 months.
What is Syncom Formulation (India) Ltd.’s market cap?
Syncom Formulation (India) Ltd.’s market cap is ₹13.67B.
When is Syncom Formulation (India) Ltd.’s upcoming earnings report date?
Syncom Formulation (India) Ltd.’s upcoming earnings report date is Nov 16, 2026 which is in 94 days.
How were Syncom Formulation (India) Ltd.’s earnings last quarter?
Syncom Formulation (India) Ltd. released its earnings results on Aug 11, 2026. The company reported ₹0.264 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Syncom Formulation (India) Ltd. overvalued?
According to Wall Street analysts Syncom Formulation (India) Ltd.’s price is currently Overvalued.
Does Syncom Formulation (India) Ltd. pay dividends?
Syncom Formulation (India) Ltd. pays a Notavailable dividend of ₹0.1 which represents an annual dividend yield of N/A. See more information on Syncom Formulation (India) Ltd. dividends here
What is Syncom Formulation (India) Ltd.’s EPS estimate?
Syncom Formulation (India) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Syncom Formulation (India) Ltd. have?
Syncom Formulation (India) Ltd. has 940,000,000 shares outstanding.
What happened to Syncom Formulation (India) Ltd.’s price movement after its last earnings report?
Syncom Formulation (India) Ltd. reported an EPS of ₹0.264 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.972%.
Which hedge fund is a major shareholder of Syncom Formulation (India) Ltd.?
Currently, no hedge funds are holding shares in IN:SYNCOMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Syncom Formulation (India) Ltd.
Established in 1985 and based in Indore, India, Syncom Formulations (India) Limited specializes in the development, marketing, and sale of a wide array of finished pharmaceutical products. The company provides an extensive portfolio addressing numerous therapeutic categories, including but not limited to pain relief, infectious diseases, cardiovascular health, mental well-being, respiratory ailments, and nutritional deficiencies, alongside specific treatments for conditions like gout and erectile dysfunction, encompassing both generic and specialized medicines. These medicinal preparations are available in various formats such as tablets, capsules, oral liquids, injectables (both liquid and dry vial), dry syrups, topical ointments, inhalers, and herbal formulations. In addition to its core pharmaceutical business, Syncom Formulations also engages in commodity trading and property leasing. The company serves the domestic Indian market and actively exports its products globally.
Technical Analysis
Bajaj Healthcare Ltd
―
Indoco Remedies Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Wanbury Limited
―